20/20 Biolabs, Inc.
AIDX Nasdaq· Services-Testing Laboratories
Last close · Oct 23, 2026
$0.24
KIRA · Stoqly’s AI analyst, in plain words
- 20/20 Biolabs, Inc. had $2.0M of revenue in fiscal 2025, up 16.7% on the year before.
- Its operating margin was −162.9%, up 161.1 pts: of every 100 in sales, about −163 is left after running the business.
- 20/20 Biolabs, Inc. lost $3.7M in fiscal 2025.
Market cap
$2.5M
P/E
—
Revenue
$2.0M
Net income
−$3.7M
Free cash flow
—
Operating margin
−162.9%
20/20 Biolabs, Inc. in 30 seconds · fiscal 2025
Are sales growing?
+16.7%
Yes. Sales grew 16.7% last year.
Does it make a profit?
−182.8%
No. It lost money last year.
How healthy are the accounts?
4 / 8
Mixed. It passes 4 of 8 health tests.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What 20/20 Biolabs, Inc. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Mar 31, 2026
- Legal name
- 20/20 Biolabs, Inc.
- CIK
- 0001139685
20/20 Biolabs, Inc. · AIDX
Results and finances
The last 2 fiscal years. Amounts in USD.
| Fiscal year | FY24 | FY25 |
|---|---|---|
| Sales and profit | ||
| Revenue | $1.8M | $2.0M |
| Revenue growth | — | 16.7% |
| Gross margin | 20.6% | 29.6% |
| Operating margin | −324.0% | −162.9% |
| Net income | −$5.6M | −$3.7M |
| Net margin | −316.8% | −182.8% |
| Diluted EPS | −$1.16 | −$0.76 |
| Cash | ||
| Cash from operations | −$2.6M | −$1.9M |
| Share count change | — | 2.7% |
| Debt and strength | ||
| Cash and short-term investments | $1.8M | $1.0M |
| Shareholders' equity | $1.5M | −$0.0M |
| Current ratio | 1.5x | 0.6x |
| Interest coverage | −450.6x | −21.3x |
| Returns and quality | ||
| Return on equity | −368.8% | −503.1% |
| Return on tangible equity | −427.1% | — |
| Piotroski F-score | — | 4 |
| Altman Z'' | −35.5 | −33.2 |
Insiders bought, 12 months
$0.0M
0 insiders
Insiders sold, 12 months
$0.0M
0 insiders
Of sales under plans
—
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
20/20 Biolabs, Inc. · AIDX
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $0.24 a share, the company is worth $2.5M.
Source: SEC EDGAR XBRL filings (CIK 0001139685). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.